Where Zentalis Pharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
Zentalis Pharma (NASDAQ:ZNTL) has received positive analyst ratings in the last quarter, with 8 bullish and 5 somewhat bullish ratings. The average 12-month price target for the company is $48.0, a decrease of 10.08% from the previous average of $53.38.
August 10, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zentalis Pharma has received positive analyst ratings, which could boost investor confidence. However, the decrease in the average price target may indicate a potential slowdown in growth.
Analyst ratings are a key indicator of a stock's potential performance. The positive ratings for Zentalis Pharma suggest that analysts are optimistic about the company's prospects, which could encourage more investors to buy the stock. However, the decrease in the average price target could be a sign that analysts are expecting slower growth in the future, which could temper investor enthusiasm.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100